

IGI LABORATORIES, INC  
Form 8-K  
July 24, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **July 24, 2014**

**IGI LABORATORIES, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation)**

**001-08568**  
**(Commission File Number)**

**01-0355758**  
**(IRS Employer Identification No.)**

**105 Lincoln Avenue**  
**Buena, New Jersey**  
**(Address of principal executive**  
**offices)**

**08310**  
**(Zip Code)**

Registrant's telephone number, including area code: **(856) 697-1441**

(Former name or former address, if changed since last report)

Edgar Filing: IGI LABORATORIES, INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02.**

**Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b)

On July 24, 2014, Damian Finio advised IGI Laboratories, Inc. (the **Company** ) that he will be resigning as a director of the Company's Board of Directors effective August 11, 2014. On July 24, 2014, the Company issued a press release announcing Mr. Finio's resignation. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01**

**Financial Statements and Exhibits.**

(d)

The following exhibit is filed with this Report:

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release of IGI Laboratories, Inc. dated July 24, 2014

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IGI LABORATORIES, INC.**

Date: July 24, 2014

By: /s/ Jenniffer Collins  
Name: Jenniffer Collins  
Title: Chief Financial Officer